Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
321-340 of 847 trials

Crohn’s Disease: MORF-057 Treatment Study

We are testing a new medication, MORF-057, for adults with moderately to severely active Crohn’s disease. The study aims to see if it improves symptoms and endoscopic results compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesGastroenterologyInternal Medicine

Fragile X Syndrome: Long-Term Study of ZYN002 Gel

We are examining the long-term safety and tolerability of a gel medication for children and young adults with Fragile X Syndrome. This study includes participants who have previously used the medication and are continuing to see if it helps manage their symptoms.

Fragile X Syndrome≤3 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurologyPediatrics

Systemic Lupus Erythematosus: Dapirolizumab Pegol Study

We are studying whether dapirolizumab pegol can improve symptoms in people with moderately to severely active systemic lupus erythematosus. This trial will also assess the safety of this new treatment when added to standard care.

Systemic Lupus Erythematosus6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease

We are studying the safety and effects of tolvaptan in infants and children with ARPKD. The trial aims to see if it helps reduce the need for kidney treatments.

Autosomal Recessive Polycystic Kidney DiseaseConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Advanced Solid Tumors: GTAEXS617 Treatment Study

We are testing a new treatment called GTAEXS617 for patients with advanced solid tumors to see how safe it is and whether it can help fight the cancer. This study will look at the treatment alone and with standard therapies.

Ovarian Epithelial CancerColorectal AdenocarcinomaNon-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Crohn's Disease: Obefazimod Study

We are testing a new medication, obefazimod, for people with moderately to severely active Crohn's disease who haven't responded to other treatments. The study aims to see if it is more effective and safe compared to a placebo.

Crohn's Disease>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Ovarian Cancer: Niraparib Rechallenge Study

We are studying whether Niraparib can help ovarian cancer patients with oligometastatic progression after surgery live longer without their cancer worsening. The trial will also assess safety and various health indicators.

Ovarian Cancer with Oligometastatic Progression1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Advanced Non-Small Cell Lung Cancer: Rilvegostomig Study

We are testing a new treatment called rilvegostomig in adults with advanced or metastatic non-small cell lung cancer. The study aims to evaluate its safety and effectiveness compared to existing therapies.

Advanced Lung CancerSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Meniscal Loss: Spongioflex® Allografts Study

We are investigating whether sterile allogeneic spongioflex® allografts can improve knee function in patients with incomplete meniscal loss. The study will also assess safety and patient satisfaction over several years.

Meniscus Tear>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOrthopedics and Traumatology

Advanced Solid Tumors: AZD0901 Treatment Study

We are investigating the safety and effectiveness of AZD0901, alone or with other cancer drugs, for patients with advanced solid tumors expressing Claudin 18.2. This study aims to understand how well this treatment may work and its potential side effects.

Gastric CancerGastroesophageal Junction CancerPancreatic Ductal AdenocarcinomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Gastric Cancer: AZD0901 Treatment Study

We are studying how well AZD0901 works and its safety compared to standard treatments for adults with advanced gastric or gastroesophageal junction cancer that has high levels of a protein called CLDN18.2.

Advanced Gastric CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Urothelial Cancer: Sacituzumab Govitecan Study

We are investigating a new treatment for patients with advanced urothelial cancer that cannot be removed by surgery. The study aims to see how effective and safe this treatment is compared to existing options.

Urothelial Cancer of the Renal Pelvis>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOncologyUrology

Ulcerative Colitis: GS-1427 Study

We are testing a new medication, GS-1427, for adults with moderately to severely active ulcerative colitis. The study aims to see if it can improve symptoms and achieve remission compared to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Chronic Inflammatory Demyelinating Polyneuropathy: Riliprubart vs. IVIg

We are studying a new treatment called riliprubart to see if it works better than the standard IVIg therapy for people with chronic inflammatory demyelinating polyneuropathy. The trial will evaluate its effects on disability, fatigue, and overall quality of life.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessStandard MedicinesInternal MedicineNeurology

Head and Neck Cancer: Amivantamab Treatment Study

We are studying the effects of amivantamab in patients with recurrent or metastatic head and neck squamous cell carcinoma. This trial looks at its use alone and with other standard treatments to see how well it works.

Recurrent Head and Neck CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Nipocalimab for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

We are studying whether nipocalimab can help adults with CIDP delay relapse and improve their symptoms compared to a placebo. This trial will also assess the safety of the treatment.

Chronic Inflammatory Demyelinating PolyneuropathyEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Progressive Pulmonary Fibrosis: Inhaled Pirfenidone Study

We are testing an inhaled medication to see if it helps improve lung function and quality of life for people with Progressive Pulmonary Fibrosis. This study compares the medication to a placebo to assess its effects over time.

Progressive Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesPulmonology

Neutropenia: Mavorixafor Study

We are investigating a new medication, mavorixafor, for people with neutropenia who have frequent infections. The study will assess how well it works and its safety compared to a placebo.

Neutropenia1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInfectious DiseasesInternal Medicine

Systemic Lupus Erythematosus: Ianalumab Study

We are evaluating a new medication, ianalumab, for patients with systemic lupus erythematosus to see if it helps improve symptoms and reduce flare-ups compared to a placebo.

Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementRheumatology

Advanced Solid Tumors: D3S-001 Treatment Study

We are testing the safety and tolerability of D3S-001, alone or with other cancer medicines, for adults with advanced solid tumors that have a KRAS p.G12C mutation. This study aims to understand how the treatment works and its effects on tumors.

Advanced Solid Tumors with a KRAS p.G12C MutationSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology